Skip to main content
Full access
Letters to the Editor
Published Online: 1 March 2018

Understanding Pregnancy’s Protective Effect on Drug Use Within a Developmental Framework

To the Editor: In the article by Kendler et al. (1), published in the October 2017 issue of the Journal, the authors analyzed Sweden’s national health registry data on nearly 150,000 women to examine pregnancy status in relation to drug use patterns, accounting for demographic, heritable, partner-related, and unmeasured individual-level confounding effects. Viewed as a natural intervention, the impact of pregnancy on drug use rivaled the effects of financial incentive–based (contingency management) interventions. Strikingly, this impact was equal, if not greater, in women with higher baseline risk factors for prenatal drug use (as shown in Table 2 in the article). The authors describe the mothers’ intrinsic motivation to protect their developing children by suspending drug use as evidence for the limitations of an exclusively brain-based view of drug abuse.
We present an expanded interpretation of the findings—one that incorporates brain-based models of addiction. Health-related behaviors of pregnant women can also be understood developmentally within a caregiving framework (2, 3). Maternal motivation to protect the fetus against drug exposure could be facilitated by highly evolutionarily conserved processes first described in mammalian species and increasingly characterized in human parental and nonparental contexts (4). These neurobiological models could be highly relevant for understanding why pregnancy confers a protective effect.
The study by Kendler and colleagues also has broader implications beyond the perinatal context. The ways that drug use and associated neuroadaptations may interrupt social and interpersonal processes have received significant attention (5). The findings from this study, together with prospective investigations that employ biomarker-verified reports of cessation during pregnancy (6, 7), now provide compelling evidence that social processes related to maternal caregiving can also interrupt addictive processes. In this way, the protective effect of pregnancy on drug use convincingly demonstrated in this study is a unique paradigm of how social and interpersonal processes can positively and powerfully influence addictive behaviors. This is encouraging because more effective and durable solutions to the treatment of substance use disorders are sorely needed.

References

1.
Kendler KS, Ohlsson H, Svikis DS, et al: The protective effect of pregnancy on risk for drug abuse: a population, co-relative, co-spouse, and within-individual analysis. Am J Psychiatry 2017; 174:954–962
2.
Massey SH, Decety J, Wisner KL, et al: Specification of change mechanisms in pregnant smokers for malleable target identification: a novel approach to a tenacious public health problem. Front Public Health 2017; 5:239
3.
Feldman R: The neurobiology of mammalian parenting and the biosocial context of human caregiving. Horm Behav 2016; 77:3–17
4.
Massey SH, Neiderhiser JM, Shaw DS, et al: Maternal self concept as a provider and cessation of substance use during pregnancy. Addict Behav 2012; 37:956–961
5.
Volkow ND, Baler RD, Goldstein RZ: Addiction: pulling at the neural threads of social behaviors. Neuron 2011; 69:599–602
6.
Massey SH, Estabrook R, O’Brien TC, et al: Preliminary evidence for the interaction of the oxytocin receptor gene (OXTR) and face processing in differentiating prenatal smoking patterns. Neurosci Lett 2015; 584:259–264
7.
Massey SH, Bublitz MH, Magee SR, et al: Maternal-fetal attachment differentiates patterns of prenatal smoking and exposure. Addict Behav 2015; 45:51–56

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 286 - 287
PubMed: 29490492

History

Accepted: December 2017
Published online: 1 March 2018
Published in print: March 01, 2018

Keywords

  1. Women
  2. Psychoactive Substance Use Disorder
  3. Other Areas Of Neuroscience
  4. Epidemiology

Authors

Details

Suena H. Massey, M.D. [email protected]
From the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago.
Katherine L. Wisner, M.D., M.S.
From the Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago.

Notes

Address correspondence to Dr. Massey ([email protected]).

Competing Interests

The content of this letter is solely the responsibility of the authors and does not necessarily represent the official views of NIDA or NIH.

Funding Information

National Institute on Drug Abuse10.13039/100000026: 5K23DA037913
Supported by NIDA grant K23 DA037913 to Dr. Massey.The Department of Psychiatry and Behavioral Sciences at Northwestern University received contractual fees for Dr. Wisner’s consultation to Quinn Emanuel Urquhart & Sullivan, LLP (New York City), which represents Pfizer. Dr. Massey reports no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share